

ASX Announcement

Change of Address

14 August 2026

In accordance with ASX Listing Rule 3.14, Ceretas Limited (ASX:CTS) ("Ceretas" or "the Company"), advises that its registered office and principal place of business have changed with immediate effect to:

Level 4, 348 Edward Street
Brisbane QLD 4000

All other contact details remain unchanged.

This announcement is authorised for release by the Board of Directors.

- ENDS -

For further information please contact

Henry Jordan

Six Degrees Investor Relations

henry.jordan@sdir.com.au

+61 (0)431 271 538

Dr Rachel de las Heras

Chief Executive Officer & Managing Director

racheldelasheras@ceretas.com.au

+61 (0)437 338 079

About Ceretas

Ceretas (ASX:CTS) is a clinical-stage medical technology company developing a portable, non-invasive therapeutic ultrasound platform to treat Alzheimer's disease and other neurodegenerative conditions.

The Ceretas device directs low-intensity focused ultrasound through the skull to act on brain tissue via two mechanisms: neuromodulation, targeting neural circuits involved in memory, cognition and the behavioural and psychological symptoms of dementia; and blood-brain barrier opening, which may facilitate clearance of disease-associated proteins and enhance delivery of therapeutic agents to the brain.

The technology is based on more than a decade of research at The University of Queensland and the Queensland Brain Institute (QBI). In 2024, QBI researchers completed a first-in-human Phase 1 trial of low-intensity focused ultrasound neuromodulation in 12

Alzheimer's participants, finding the treatment to be fast, safe and well tolerated, with encouraging early signals of benefit for behavioural symptoms. The results were published in Brain Communications in December 2025.

Ceretas is preparing to commence its Phase 2 CERE-CALM trial (ACTRN12626000738325), evaluating the platform in Alzheimer's patients with behavioural and psychological symptoms of dementia. QBI researchers are separately running their Phase 2 AGIFUS trial (ACTRN12626000687392), evaluating the same technology in Alzheimer's-related agitation, funded independently by Queensland Health.